Robin Schaefer
Overview
Explore the profile of Robin Schaefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schaefer R, Donaldson L, Chigome A, Escudeiro Dos Santos M, Lamprianou S, Ndembi N, et al.
Drug Saf
. 2025 Jan;
48(3):209-216.
PMID: 39873899
HIV-prevention efforts focusing on women of child-bearing potential are needed to end the HIV epidemic in the African region. The use of antiretroviral drugs as pre-exposure prophylaxis (PrEP) is a...
2.
Schaefer R, Donaldson L, Leus M, Osakwe C, Chimukangara B, Dalal S, et al.
PLOS Glob Public Health
. 2024 Oct;
4(10):e0003878.
PMID: 39446892
No abstract available.
3.
Schaefer R, Ayvaz A, Hoffman C, Yann M, Rooney Z, Leus M, et al.
Clin Transl Sci
. 2024 Oct;
17(10):e70051.
PMID: 39425910
Developing safe and effective drugs and other medical products is a complex and costly process. Drug development has been, historically, commonly competitive and uncollaborative, and this tendency toward a lack...
4.
Murdock N, Alajaji N, Schaefer R, Boone C, Campo R, Dore G, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae337.
PMID: 38983711
New long-acting HIV treatment products have the potential to change the HIV epidemic in the United States and globally. Phase 3 clinical trials of HIV treatments tend to underrepresent populations...
5.
Spielman E, Mello M, Schaefer R, Ong J, Schmidt H, Henderson M, et al.
Sex Transm Infect
. 2024 Jun;
100(6):343-348.
PMID: 38897729
Objectives: People who use or would benefit from pre-exposure prophylaxis (PrEP) for HIV infection are disproportionately affected by sexually transmitted infections (STIs). Integrating STI services when offering PrEP fosters synergies...
6.
Cox S, Wu L, Wittenauer R, Clark S, Roberts D, Nwogu I, et al.
Lancet HIV
. 2024 Feb;
11(3):e167-e175.
PMID: 38301668
Background: Community-based oral pre-exposure prophylaxis (PrEP) provision has the potential to expand PrEP coverage. HIV self-testing can facilitate PrEP community-based delivery but might have lower sensitivity than facility-based HIV testing,...
7.
Schaefer R, Peralta H, Radebe M, Baggaley R
J Adolesc Health
. 2023 Nov;
73(6S):S8-S10.
PMID: 37953013
No abstract available.
8.
Lorenzetti L, Dinh N, van der Straten A, Fonner V, Ridgeway K, Rodolph M, et al.
J Int AIDS Soc
. 2023 Jul;
26 Suppl 2:e26107.
PMID: 37439057
Introduction: Pre-exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long-acting injectable cabotegravir (CAB-LA) as PrEP. In considering CAB-LA as an additional...
9.
Warren M, Nyagah W, Verde Hashim C, Rodolph M, Schaefer R, Schmidt H, et al.
J Int AIDS Soc
. 2023 Jul;
26 Suppl 2:e26094.
PMID: 37439050
Introduction: Data from two randomized controlled trials (RCTs) showed that injectable cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) was efficacious in reducing HIV acquisition. The US Food and Drug Administration approved...
10.
Henderson M, Schmidt H, Chitembo L, Peralta H, Alaama A, Johnson C, et al.
AIDS Behav
. 2023 Jun;
27(11):3755-3766.
PMID: 37351685
Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention....